Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients

[1] Bastian PJ(2009)Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 1321-1332

[2] Carter BH(2013)Limitations of basing screening policies on screening trials: the US preventive services task force and prostate cancer screening Med Care 51 295-300

[3] Bjartell A(2018)Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients Prostate 78 48-53

[4] Seitz M(2017)PSMA ligands for PET imaging of prostate cancer J Nucl Med 58 1545-1552

[5] Stanislaus P(2017)Prostate-specific membrane antigen ligands for imaging and therapy J Nucl Med 58 67S-76S

[6] Montorsi F(2015)Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy J Nucl Med 56 668-674

[7] Etzioni R(2016)68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients Eur J Nucl Med Mol Imaging 43 34-41

[8] Gulati R(2012)[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur J Nucl Med Mol Imaging 39 1085-1086

[9] Cooperberg M(2016)68 Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment BJU Int 117 732-739

[10] Penson D(2013)PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur J Nucl Med Mol Imaging 40 486-495

[1] Bastian PJ(2009)Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 1321-1332

[2] Carter BH(2013)Limitations of basing screening policies on screening trials: the US preventive services task force and prostate cancer screening Med Care 51 295-300

[3] Bjartell A(2018)Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients Prostate 78 48-53

[4] Seitz M(2017)PSMA ligands for PET imaging of prostate cancer J Nucl Med 58 1545-1552

[5] Stanislaus P(2017)Prostate-specific membrane antigen ligands for imaging and therapy J Nucl Med 58 67S-76S

[6] Montorsi F(2015)Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy J Nucl Med 56 668-674

[7] Etzioni R(2016)68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients Eur J Nucl Med Mol Imaging 43 34-41

[8] Gulati R(2012)[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur J Nucl Med Mol Imaging 39 1085-1086

[9] Cooperberg M(2016)68 Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment BJU Int 117 732-739

[10] Penson D(2013)PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur J Nucl Med Mol Imaging 40 486-495